Comparison of patients with HCC with and without MASLD after surgical resection [0.03%]
与MASLD患者相比，肝癌切除术后患者的临床结局分析
Chia-Jung Ho,Hao-Jan Lei,Chun-Ting Ho et al.
Chia-Jung Ho et al.
Background & aims: The prognostic impact of metabolic dysfunction-associated steatotic liver disease (MASLD) on hepatocellular carcinoma (HCC) after surgical resection remains uncertain. In this study, we compared the cli...
Temporal trends and racial/ethnic disparities in hepatocellular carcinoma incidence in the US between 2000-2022 [0.03%]
2000年至2022年美国肝细胞癌发病率的 temporal 走势及种族差异
Wenzhan Jing,Hang Pham,Samuel So
Wenzhan Jing
Background & aims: Hepatocellular carcinoma (HCC) in the US is largely driven by chronic hepatitis B in non-Hispanic Asians/Pacific Islanders (NH API) and chronic hepatitis C and metabolic dysfunction-associated steatotic...
PHENO-RAG: An artificial intelligence tool for guideline-informed management decisions in hepatocellular carcinoma [0.03%]
基于指南的肝细胞癌管理决策人工智能工具PHENO-RAG
Ciro Celsa,Mauro Giuffrè,Gabriele Di Maria et al.
Ciro Celsa et al.
Background & aims: Management of hepatocellular carcinoma (HCC) poses unique challenges due to its development in the context of chronic liver disease and the availability of multiple treatment options. Although multidisc...
Evaluation and management of primary sclerosing cholangitis patients awaiting liver transplantation [0.03%]
原发性硬化性胆管炎肝移植患者的评估和管理
Alexandra D Frolkis,Jeremy S Nayagam,Alessandro Parente et al.
Alexandra D Frolkis et al.
Primary sclerosing cholangitis (PSC) is a rare, progressive cholestatic liver disease characterised by biliary strictures, increased risk of cholangiocarcinoma, and a strong association with inflammatory bowel disease. Despite its low preva...
AI-assisted fibrosis scoring in MASH: Exploring pathologist decision-making with an SHG-based AI digital pathology tool [0.03%]
基于SHG的数字病理人工智能工具在MASH中的辅助纤维化评分：探讨病理学家的决策过程
Desiree Abdurrachim,Aileen Wee,Gwyneth Soon et al.
Desiree Abdurrachim et al.
Background & aims: Intra- and inter-reader variability complicates liver biopsy scoring for metabolic dysfunction-associated steatohepatitis (MASH). AI-powered digital pathology (AI-DP) is emerging as a tool to assist pat...
Single-photon emission computed tomography functional liver imaging to facilitate reirradiation for liver malignancies: A phase I trial [0.03%]
单光子发射计算机断层扫描肝脏功能成像指导肿瘤再放疗一期临床试验
Enoch Chang,Emma B Holliday,Janio Szklaruk et al.
Enoch Chang et al.
Background & aims: This phase I trial evaluated the safety of hypofractionated liver reirradiation (reRT) with preferential sparing of functional liver identified by technetium-99m sulfur colloid single-photon emission co...
CD36-PPARγ-SPP1 axis mediates hepatocyte-macrophage coordination to drive MASLD-related liver fibrosis [0.03%]
CD36-PPARγ-SPP1轴介导的肝细胞-巨噬细胞相互作用驱动MASLD相关性肝纤维化
Zhe Dai,Xiaoman Liu,Yining Liang et al.
Zhe Dai et al.
Background & aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by profound remodeling of hepatic macrophages, including the emergence of lipid-associated macrophages (LAMs). However, ...
Efficacy and safety of GLP-1 receptor agonists in MASH with fibrosis: A systematic review and meta-analysis [0.03%]
胰高血糖素样肽1受体激动剂治疗代谢相关脂肪性肝病合并纤维化的有效性和安全性：系统评价和 meta 分析
Rafael Dos Santos Borges,Eliabe S Abreu,Giovanni Gosch Berton et al.
Rafael Dos Santos Borges et al.
Background & aims: Metabolic dysfunction-associated steatohepatitis (MASH) is a risk factor for progressive hepatic fibrosis and cirrhosis. The role of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in the treatment...
The Elucidating Pathways of Steatohepatitis (EPoS) staging system: A reproducible 7-tiered fibrosis scoring system in MASLD [0.03%]
肝硬化无创评估的明路（EPoS）分期系统：MASLD纤维化分级评分系统的可重复性及7级评分标准
Dina G Tiniakos,Pierre Bedossa,Johanna Arola et al.
Dina G Tiniakos et al.
Background & aims: Fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD) is histologically staged using the 5-tiered NASH CRN system, which has limited resolution for advanced fibrosis stages that a...
CAR-T cells targeting activated hepatic stellate cells ameliorate liver fibrosis in mouse models [0.03%]
针对活化肝星状细胞的CAR-T细胞可改善小鼠模型肝纤维化
Yang-Wen-Qing Zhang,Hui Ren,Minghe Zhang et al.
Yang-Wen-Qing Zhang et al.
Background & aims: The transition to liver fibrosis represents a crucial and irreversible transition in chronic liver diseases, with liver fibrosis being a key driver of the progression to life-threatening complications, ...